Pulmonx Corporation (NASDAQ:LUNG) Receives Consensus Recommendation of “Hold” from Brokerages

Pulmonx Corporation (NASDAQ:LUNG) has earned a consensus recommendation of “Hold” from the ten analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $7.6643.

A number of analysts have recently issued reports on the company. Piper Sandler lowered Pulmonx from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $9.00 to $2.50 in a research report on Thursday, July 31st. Weiss Ratings restated a “sell (e+)” rating on shares of Pulmonx in a research note on Wednesday, October 8th. Lake Street Capital dropped their price objective on Pulmonx from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, July 31st. Wells Fargo & Company cut their target price on Pulmonx from $6.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Friday, August 1st. Finally, Wall Street Zen cut Pulmonx from a “hold” rating to a “sell” rating in a research note on Friday, October 3rd.

Pulmonx Trading Down 3.2%

LUNG opened at $1.52 on Tuesday. The firm has a market capitalization of $61.94 million, a P/E ratio of -1.06 and a beta of 0.42. The firm’s 50 day moving average is $1.66 and its 200-day moving average is $2.86. The company has a quick ratio of 4.63, a current ratio of 5.35 and a debt-to-equity ratio of 0.54. Pulmonx has a 52-week low of $1.47 and a 52-week high of $9.37.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings results on Wednesday, July 30th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.02. Pulmonx had a negative net margin of 62.88% and a negative return on equity of 69.76%. The business had revenue of $23.86 million during the quarter, compared to analyst estimates of $23.46 million. Pulmonx has set its FY 2025 guidance at EPS. Analysts expect that Pulmonx will post -1.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Pulmonx

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Rhumbline Advisers raised its stake in shares of Pulmonx by 4.6% in the 1st quarter. Rhumbline Advisers now owns 55,958 shares of the company’s stock valued at $377,000 after purchasing an additional 2,455 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Pulmonx by 1.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 320,946 shares of the company’s stock valued at $2,160,000 after buying an additional 5,414 shares during the last quarter. Vontobel Holding Ltd. acquired a new stake in Pulmonx during the first quarter valued at approximately $82,000. Corton Capital Inc. bought a new position in Pulmonx during the 2nd quarter worth approximately $32,000. Finally, R Squared Ltd bought a new position in Pulmonx during the 2nd quarter worth approximately $41,000. Institutional investors own 91.04% of the company’s stock.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.